title: Trends in relative survival for ovarian cancer from 1975 to 2011.
abstract: OBJECTIVE
  To examine relative survival (a metric that incorporates changes in survival within a population) in women with ovarian cancer from 1975 to 2011.
  
  
  METHODS
  Women diagnosed with ovarian cancer from 1975 to 2011 and recorded in the National Cancer Institute's Surveillance, Epidemiology, and End Results database were examined. Relative survival, estimated as the ratio of the observed survival of cancer patients (all-cause mortality) to the expected survival of a comparable group from the general population, was matched to the patients with the main factors that are considered to affect patient survival such as age, calendar time, and race. Hazard ratios were adjusted for age, race, year of diagnosis, time since diagnosis, and the interaction of age and years since diagnosis (except for stage II).
  
  
  RESULTS
  A total of 49,932 women were identified. For stage I ovarian cancer, the adjusted excess hazard ratio for death in 2006 was 0.51 (95% confidence interval [CI] 0.41-0.63) compared with those diagnosed in 1975. The reduction in excess mortality remained significant when compared with 1980 and 1985. For women with stage III-IV tumors, the excess hazard of mortality was lower in 2006 compared with all other years of study ranging from 0.49 (95% CI 0.44-0.55) compared with 1975 to 0.93 (95% CI 0.87-0.99) relative to 2000. For women aged 50-59 years, 10-year relative survival was 0.85 (99% CI 0.61-0.95) for stage I disease and 0.18 (99% CI 0.10-0.27) for stage III-IV tumors. For women aged 60-69 years, the corresponding 10-year relative survival estimates were 0.89 (99% CI 0.58-0.98) and 0.15 (99% CI 0.09-0.21).
  
  
  CONCLUSIONS
  Relative survival has improved for all stages of ovarian cancer from 1975 to 2011.
  
  
  METHODS
  II.
authors.affiliation: Departments of Obstetrics and Gynecology and Medicine and the Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, the Department of Epidemiology, Mailman School of Public Health, Columbia University, and New York Presbyterian Hospital, New York, New York.
authors.forename: Jason D
authors.initials: JD
authors.lastname: Wright
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Ana I
authors.initials: AI
authors.lastname: Tergas
authors.forename: Sonali
authors.initials: S
authors.lastname: Patankar
authors.forename: William M
authors.initials: WM
authors.lastname: Burke
authors.forename: June Y
authors.initials: JY
authors.lastname: Hou
authors.forename: Alfred I
authors.initials: AI
authors.lastname: Neugut
authors.forename: Cande V
authors.initials: CV
authors.lastname: Ananth
authors.forename: Dawn L
authors.initials: DL
authors.lastname: Hershman
mesh_terms: D000328:Adult; D001741:Black or African American / Q000706:statistics & numerical data; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000208:ethnology / Q000401:mortality* / Q000473:pathology; D018426:SEER Program; D015996:Survival Rate / Q000639:trends; D044465:White People / Q000706:statistics & numerical data; D055815:Young Adult